The content on this site is intended for healthcare professionals only
Dr George Simon gives his thoughts on the latest key studies in locally and advanced immunotherapy developments and new agents in lung cancer, from ASCO Direct Highlights 2022.
He discusses the results of the FDA analysis which found using chemotherapy plus immunotherapy was numerically superior versus immunotherapy alone in small cell lung cancers for most patients.
Dr Simon then discusses the analysis of the S1800 data from the subset study of lung map where progression free survival was superior for pembrolizumab plus bevacizumab versus standard of care.
Further abstracts in small cell lung cancer are discussed including Skyscraper 2 and another study which found twice a day radiation therapy, compared to once a day, improved the long term quality of life for patients.
Dr Simon concludes by discussing new agents, such as the IL27 inhibitor.
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
